Related Experiment Videos
Chronic rejection and late renal allograft dysfunction
1Children's Hospital, University Hospital, University of Helsinki, Finland.
Insights
Pediatric kidney transplant recipients face chronic rejection, limiting long-term graft survival. Minimizing early injury is key to improving allograft half-life and reducing retransplantation needs.
Area of Science:
- Nephrology
- Transplantation Immunology
- Pediatric Nephrology
Background:
- Renal transplantation is the standard treatment for end-stage kidney disease in children.
- Short-term outcomes have improved, but long-term allograft survival remains unchanged due to chronic rejection.
- Chronic renal allograft rejection is a significant barrier to prolonged graft function.
Purpose of the Study:
- To clarify the multifactorial pathogenesis of chronic renal allograft rejection.
- To identify strategies for attenuating the progression of chronic rejection.
- To explore potential therapeutic approaches for improving allograft half-life in pediatric recipients.
Main Methods:
- Review of recent advancements in understanding the pathogenesis of chronic renal allograft rejection.
- Analysis of immunological and non-immunological injury mechanisms.
- Evaluation of vascular remodeling processes, including cytokine release and smooth muscle cell proliferation.
Main Results:
- Early injury initiates a cascade involving vascular remodeling, arteriosclerosis, and ischemia.
- Reduced functioning renal mass triggers secondary kidney-specific mechanisms that accelerate chronic rejection.
- Current therapeutic attempts have shown promise but no single optimal therapy exists.
Conclusions:
- Minimizing early immunological and non-immunological injury is crucial for preventing chronic rejection progression.
- New therapeutic agents and a comprehensive treatment approach may significantly prolong allograft half-life.
- Improved graft survival in pediatric patients could reduce the need for retransplantation in adulthood.
Abstract:
Renal transplantation is currently standard therapy for end-stage kidney disease for children. Despite the considerable improvement in short-term results, the expected allograft half-life has remained the same. This is due to chronic rejection/late graft dysfunction which has proved resistant to therapeutic attempts. During the last few years the multifactorial pathogenesis of chronic renal allograft rejection has been clarified to some extent. Early injury by immunological and non-immunological mechanisms is followed by vascular remodelling due to repetitive cycles of cytokine release, upregulation of growth factors, and vascular smooth muscle cell proliferation. This leads to typical concentric arteriosclerosis and ischemia. Secondary kidney-specific mechanisms are initiated by the reduction in functioning renal mass and lead to gradual progression of chronic rejection. There is no single optimal therapy. Several attempts to influence the pathophysiological cascade have been promising. Attention should be focused on minimizing early immunological/non-immunological injury in order to attenuate future progression of chronic rejection. A significant prolongation of allograft half-life may be achieved during the next decade with the introduction of new therapeutic agents and comprehensive approach to treatment. This would be especially beneficial for pediatric recipients, reducing the need for retransplantation in adulthood.